UBS sets USD 673 target for Medpace stock

Published on 10/06/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 17.20 percent to USD 707.33 million. Medpace stock costs EUR 557.60 on October 6, 2026 after EUR 552.90.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Medpace (ISIN US58506Q1094) was trading at EUR 557.60 at Lang & Schwarz on October 6, 2026 at 3:10 p.m. CEST, plus 0.85 percent versus the prior close of EUR 552.90. The latest analyst action came from UBS, which resumed coverage with a Neutral rating and a USD 673.00 price target on September 30, 2026, according to Markets Insider.

UBS sets a clear valuation marker

UBS cited a survey of 50 biopharma sponsors and research and development spending in its sector view, while also flagging Medpace's high CRO valuation and bookings volatility, Markets Insider reported on September 30, 2026. The target is stated in USD, so it is not netted against the Lang & Schwarz quote in EUR.

The target nevertheless gives investors a concrete reference point ahead of the next company update. Medpace's contract research organization model serves biotechnology, pharmaceutical and medical device customers through clinical development services from Phase I to Phase IV.

Second-quarter growth remains measurable

Medpace reported USD 707.33 million of revenue for the second quarter of 2026, up 17.20 percent from USD 603.30 million in the second quarter of 2025, according to Business Wire. The comparison shows that the latest reported growth came from a higher revenue base rather than a flat year-on-year result.

Adjusted earnings per share reached USD 4.25 in the same quarter, versus the USD 3.98 consensus estimate. The USD 0.27 difference provides a second quantified comparison, although the next result will determine whether the growth rate and earnings delivery continue into the second half of 2026.

October 21 brings the next test

Medpace plans to report third-quarter 2026 financial results after the market close on October 21, 2026, with a conference call scheduled for October 22, 2026 at 9:00 a.m. ET, according to Business Wire. That date puts the next earnings release directly after the UBS target reset and gives the market a defined checkpoint for bookings, revenue and earnings.

Medpace price remains above prior close

At Lang & Schwarz, Medpace was trading at EUR 557.60 on October 6, 2026 at 3:10 p.m. CEST, up 0.85 percent from the EUR 552.90 prior close. The Nasdaq-listed company had a market capitalization of USD 17.3 billion as of October 5, 2026, while its 52-week range was USD 373.00 to USD 677.90.